Fibrinogen is an extraordinary molecule by any estimation. It is large, structurally intricate,
and circulates at high concentrations. Its biological end product, insoluble fibrin (ogen) or …

Multiple mechanisms mediate thrombin generation and consequently the thrombin
concentration present during fibrin formation. First, the levels of pro-and anticoagulants …

New evidence has stirred up a long‐standing but undeservedly forgotten interest in the role
of erythrocytes, or red blood cells (RBCs), in blood clotting and its disorders. This review …

Since its discovery over 350 years ago, studies of fibrinogen have revealed remarkable
characteristics. Its complex structure as a large (340 kD a) hexameric homodimer supports …

Red blood cells (RBCs) have historically been considered passive bystanders in
thrombosis. However, clinical and epidemiological studies have associated quantitative and …

In response to vessel injury (or other pathological conditions), the hemostatic process is
activated, resulting in a fibrous, cellular-rich structure commonly referred to as a blood clot …

A State of the Art lecture titled “Blood Clot Contraction: Mechanisms, Pathophysiology, and
Disease” was presented at the International Society on Thrombosis and Haemostasis (ISTH) …

In contrast to an obsolete notion that erythrocytes, or red blood cells (RBC s), play a passive
and minor role in haemostasis and thrombosis, over the past decades there has been …

While hemostasis is the physiological process that prevents blood loss after vessel injury,
thrombosis is often portrayed as a pathologic event involving blood coagulation and platelet …

Deep vein thrombosis (DVT) is a major origin of morbidity and mortality. While DVT has long
been considered as blood coagulation disorder, several recent lines of evidence …